Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Janux Therapeutics (JANX) EBITDA: 2020-2024

Historic EBITDA for Janux Therapeutics (JANX) over the last 5 years, with Dec 2024 value amounting to -$67.5 million.

  • Janux Therapeutics' EBITDA fell 26.25% to -$23.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$105.2 million, marking a year-over-year decrease of 104.08%. This contributed to the annual value of -$67.5 million for FY2024, which is 20.33% down from last year.
  • Janux Therapeutics' EBITDA amounted to -$67.5 million in FY2024, which was down 20.33% from -$56.1 million recorded in FY2023.
  • In the past 5 years, Janux Therapeutics' EBITDA ranged from a high of -$6.8 million in FY2020 and a low of -$67.5 million during FY2024.
  • For the 3-year period, Janux Therapeutics' EBITDA averaged around -$62.6 million, with its median value being -$64.3 million (2022).
  • As far as peak fluctuations go, Janux Therapeutics' EBITDA crashed by 385.58% in 2021, and later rose by 12.80% in 2023.
  • Over the past 5 years, Janux Therapeutics' EBITDA (Yearly) stood at -$6.8 million in 2020, then tumbled by 385.58% to -$32.9 million in 2021, then plummeted by 95.26% to -$64.3 million in 2022, then grew by 12.80% to -$56.1 million in 2023, then decreased by 20.33% to -$67.5 million in 2024.